A Phase 2 interventional study of PF-04171327 and PF-04171327 in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 93 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-04.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Arthritis, Rheumatoid by Pfizer — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Pfizer.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 25th largest by enrollment of the 86 interventional ones that give a count, is one of 9 that started in 2011, is one of 28 in phase 2, and was the 91st registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 152 studies in Arthritis, Rheumatoid by Pfizer are open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of
Ages 18+
Pfizer
Ages 18–70
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 29 · Phase 3 18 · Phase 4 17
First in 2003; this study’s year is marked. 9 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 323 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 155 across the 86 interventional studies, 421 across the 63 observational. Of the 149 that completed or were terminated, 105 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the safety and efficacy of multiple doses of PF-04171327, an experimental glucocorticoid drug, to prednisone at 5 mg or 10 mg and placebo in the treatment of rheumatoid arthritis. All subjects will also be receiving background treatment of methotrexate for their rheumatoid arthritis. Study medication will be given for eight weeks followed by a 4 week period during which the dose of study medication will be gradually reduced. The efficacy of the study medications will be determined by assessing severity of the rheumatoid arthritis during the study and safety will be determined by adverse event reporting, laboratory tests and biomarker analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: PF-04171327
Drug: PF-04171327
Drug: PF-04171327
Drug: PF-04171327
Drug: prednisone
Other: prednisone
Other: placebo
1 mg tablet once daily (QD) for 8 weeks
5 mg tablet once daily (QD) for 8 weeks
10 mg tablet once daily (QD) for 8 weeks
15 mg tablet once daily (QD) for 8 weeks
5 mg capsule once daily for 8 weeks
10 mg capsule once daily for 8 weeks
placebo (tablet or capsule) once daily (QD) for 8 weeks
Percentage of Participants Achieving a 20% Improvement in American College of Rheumatology (ACR) Criteria at Week 8
ACR20 response: greater than or equal to (≥) 20 percent (%) improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
Time frame: Week 8
Mean Percent Change From Baseline in 0 Hour Procollagen Type 1 N Terminal Propeptide (P1NP) at Week 8 (Comparisons to Prednisone 5 mg)
Change from baseline in P1NP at week 8 is presented in this outcome measure.
Time frame: Week 8
Mean Percent Change From Baseline in 0 Hour Urinary N Telopeptide/Urinary Creatinine (uNTx/uCr) at Week 8 (Comparisons to Prednisone 5 mg)
Change from baseline in uNTx/uCr at week 8 is presented in this outcome measure.
Time frame: Week 8
Percentage of Participants Achieving ACR20 Response at Weeks 2, 4, and 12 (Comparisons to Placebo, and Prednisone 10 mg)
ACR20 response: greater than or equal to (≥) 90 percent (%) improvement in tender or swollen joint counts and 90% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.
Time frame: Weeks 2, 4, and 12 (taper period)
Percentage of Participants Achieving ACR50 Response at Weeks 2, 4, 6, 8 and 12 (Comparisons to Placebo, and Prednisone 10 mg)
ACR50 response: greater than or equal to (≥) 50 percent (%) improvement in tender or swollen joint counts and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.
Time frame: Weeks 2, 4, 6, 8, and 12 (taper period)
Percentage of Participants Achieving ACR70 Response at Weeks 2, 4, 6, 8 and 12 (Comparisons to Placebo, and Prednisone 10 mg)
ACR70 response: greater than or equal to (≥) 70 percent (%) improvement in tender or swollen joint counts and 70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.
Time frame: Weeks 2, 4, 6, 8, and 12 (taper period)
Change From Baseline in Tender-Joint Counts at Weeks 2, 4, 6, 8 (Comparisons to Placebo, and Prednisone 10 mg)
Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline in Tender-Joint Counts at Week 12 (Descriptive Statistics)
Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.
Time frame: Week 12
Change From Baseline in Swollen-Joint Counts at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline in Swollen-Joint Counts at Week 12 (Descriptive Statistics)
Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.
Time frame: Week 12
Change From Baseline in C Reactive Protein (CRP) at Weeks 2, 4, 6, and 8 (Comparisons to Placebo and Prednisone 10 mg)
The CRP was collected at each applicable clinic visit and analyzed by a central laboratory. In order to assist with the data clean-up at the end of the study, the CRP results were unblinded to the sponsor at the time of the last subject's last visit. All statistics presented below are derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction and baseline value; unstructured covariance matrix was used.
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline of CRP at Week 12 (Descriptive Statistics)
The CRP was collected at each applicable clinic visit and analyzed by a central laboratory. In order to assist with the data clean-up at the end of the study, the CRP results were unblinded to the sponsor at the time of the last subject's last visit.
Time frame: Week 12
Change From Baseline in Patient Global Assessment of Arthritis at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The subject's response was recorded using a 100 mm Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline in Patient Global Assessment of Arthritis at Week 12 (Descriptive Statistics)
Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The subject's response was recorded using a 100 mm Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
Time frame: Week 12
Change From Baseline in Physician Global Assessment of Arthritis at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
The investigator assessed how the participant's overall arthritis appears at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline in Physician Global Assessment of Arthritis at Week 12 (Descriptive Statistics)
The investigator assessed how the participant's overall arthritis appears at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.
Time frame: Week 12
Change From Baseline in Pain VAS at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Participants assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponds to the magnitude of their pain.
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline in Pain VAS at Week 12 (Descriptive Statistics)
Participants assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponds to the magnitude of their pain.
Time frame: Week 12
Change From Baseline in HAQ-DI at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline in HAQ-DI at Week 12 (Descriptive Statistics)
Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Week 12
Change From Baseline in Disease Activity Score (DAS) 28-3 CRP at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline in DAS 28-3 CRP at Week 12 (Descriptive Statistics)
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.
Time frame: Week 12
Change From Baseline in DAS28-4(CRP) at Weeks 2, 4, 6, and 8 (Comparisons to Placebo, and Prednisone 10 mg)
DAS28-4 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission. All statistics presented below are derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction and baseline value; unstructured covariance matrix was used.
Time frame: Weeks 2, 4, 6, and 8
Change From Baseline in DAS28-4(CRP) at Week 12 (Descriptive Statistics)
DAS28-4 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.
Time frame: Week 12
Change From Baseline in SF-36v2 Mental Component Scores at Weeks 4 and 8 (Comparisons to Placebo, and Prednisone 10 mg)
The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.
Time frame: Weeks 4 and 8
Change From Baseline in SF-36v2 Mental Component Scores at Week 12 (Descriptive Statistics)
The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.
Time frame: Week 12
Change From Baseline in SF-36v2 Physical Component Scores at Weeks 4 and 8 (Comparisons to Placebo, and Prednisone 10 mg)
The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.
Time frame: Weeks 4 and 8
Change From Baseline in SF-36v2 Physical Component Scores at Week 12 (Descriptive Statistics)
The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.
Time frame: Week 12
This multi-center, randomized, double-blind, parallel-group, active and placebo-controlled study randomized 323 participants in at 73 centers. An additional 34 centers had no screening activities, but received study medication; and an additional 17 centers had at least 1 participant screened, but did not randomize any participants.
| Milestone | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Started | 45 | 47 | 45 | 48 | 45 | 46 | 47 |
| Completed | 42 | 40 | 44 | 43 | 44 | 44 | 39 |
| Not completed | 3 | 7 | 1 | 5 | 1 | 2 | 8 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 2 | 0 | 2 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Medication error without associated ae | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 2 | 3 | 1 | 2 | 0 | 2 | 3 |
ACR20 response: greater than or equal to (≥) 20 percent (%) improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
| Percentage of participants | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving a 20% Improvement in American College of Rheumatology (ACR) Criteria at Week 8 | 47 | 61 | 69 | 73 | 51 | 71 | 37 |
Change from baseline in P1NP at week 8 is presented in this outcome measure.
| Percent change | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Mean Percent Change From Baseline in 0 Hour Procollagen Type 1 N Terminal Propeptide (P1NP) at Week 8 (Comparisons to Prednisone 5 mg) | -3.25 ± 5.50 | -11.60 ± 5.55 | -9.96 ± 5.49 | -16.63 ± 5.55 | -4.89 ± 5.55 | -20.14 ± 5.50 | 14.19 ± 5.56 |
Change from baseline in uNTx/uCr at week 8 is presented in this outcome measure.
| Percent change | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Mean Percent Change From Baseline in 0 Hour Urinary N Telopeptide/Urinary Creatinine (uNTx/uCr) at Week 8 (Comparisons to Prednisone 5 mg) | 6.08 ± 5.83 | -3.78 ± 5.88 | 6.96 ± 5.86 | 15.57 ± 5.83 | 2.74 ± 5.87 | -9.14 ± 5.83 | 3.81 ± 5.88 |
ACR20 response: greater than or equal to (≥) 90 percent (%) improvement in tender or swollen joint counts and 90% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.
| Percentage of Participants | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Week 2 | 31.82 ± 7.02 | 32.61 ± 6.91 | 40.00 ± 7.30 | 42.55 ± 7.21 | 28.89 ± 6.75 | 36.96 ± 7.11 | 20.45 ± 6.08 |
| Week 4 | 31.11 ± 6.90 | 55.32 ± 7.25 | 66.67 ± 7.02 | 53.19 ± 7.27 | 48.89 ± 7.45 | 65.22 ± 7.02 | 40.00 ± 7.30 |
| Week 12 | 35.56 ± 7.13 | 48.94 ± 7.29 | 55.56 ± 7.40 | 38.30 ± 7.09 | 48.89 ± 7.45 | 56.52 ± 7.30 | 33.33 ± 7.02 |
ACR50 response: greater than or equal to (≥) 50 percent (%) improvement in tender or swollen joint counts and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) participant's assessment of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.
| Percentage of Participants | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Week 2 | 4.55 ± 3.14 | 8.70 ± 4.15 | 8.89 ± 4.24 | 25.53 ± 6.36 | 2.22 ± 2.19 | 19.57 ± 5.84 | 6.82 ± 3.79 |
| Week 4 | 8.89 ± 4.24 | 23.40 ± 6.17 | 35.56 ± 7.13 | 27.66 ± 6.52 | 11.11 ± 4.68 | 30.43 ± 6.78 | 11.11 ± 4.68 |
| Week 6 | 11.11 ± 4.68 | 27.66 ± 6.52 | 40.00 ± 7.30 | 42.55 ± 7.21 | 24.44 ± 6.40 | 36.96 ± 7.11 | 15.56 ± 5.40 |
| Week 8 | 22.22 ± 6.19 | 31.91 ± 6.79 | 48.89 ± 7.45 | 42.55 ± 7.21 | 26.67 ± 6.59 | 45.65 ± 7.34 | 13.33 ± 5.16 |
| Week 12 | 17.78 ± 5.69 | 21.28 ± 5.96 | 24.44 ± 6.40 | 17.02 ± 5.48 | 26.67 ± 6.59 | 23.91 ± 6.28 | 17.78 ± 5.69 |
ACR70 response: greater than or equal to (≥) 70 percent (%) improvement in tender or swollen joint counts and 70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.
| Percentage of Participants | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Week 2 | 0.0 | 4.35 | 2.22 | 6.38 | 2.22 | 8.70 | 0.0 |
| Week 4 | 0.0 | 8.51 | 15.56 | 17.02 | 4.44 | 15.22 | 0.0 |
| Week 6 | 2.22 | 12.77 | 13.33 | 17.02 | 6.67 | 21.74 | 4.44 |
| Week 8 | 8.89 | 17.02 | 26.67 | 21.28 | 6.67 | 26.09 | 11.11 |
| Week 12 | 6.67 | 12.77 | 6.67 | 8.51 | 11.11 | 10.87 | 6.67 |
Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.
| Joints | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Week 2 | -4.08 ± 0.74 | -5.55 ± 0.72 | -4.97 ± 0.73 | -5.65 ± 0.72 | -3.88 ± 0.73 | -5.38 ± 0.72 | -1.95 ± 0.74 |
| Week 4 | -5.97 ± 0.80 | -6.99 ± 0.79 | -7.01 ± 0.80 | -6.93 ± 0.79 | -5.79 ± 0.80 | -7.44 ± 0.79 | -4.16 ± 0.80 |
| Week 6 | -6.87 ± 0.87 | -8.83 ± 0.87 | -8.37 ± 0.87 | -8.31 ± 0.86 | -6.91 ± 0.87 | -8.75 ± 0.86 | -4.64 ± 0.87 |
| Week 8 | -7.06 ± 0.91 | -8.65 ± 0.92 | -9.46 ± 0.91 | -9.17 ± 0.91 | -7.00 ± 0.91 | -8.84 ± 0.90 | -4.27 ± 0.92 |
Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.
| Joints | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Tender-Joint Counts at Week 12 (Descriptive Statistics) | -6.25 ± 6.77 | -7.24 ± 6.13 | -6.16 ± 6.40 | -6.47 ± 7.54 | -7.07 ± 5.89 | -8.16 ± 4.66 | -5.59 ± 6.67 |
Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.
| Joints | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Week 2 | -3.42 ± 0.62 | -4.70 ± 0.61 | -4.27 ± 0.62 | -5.36 ± 0.61 | -3.65 ± 0.62 | -5.04 ± 0.61 | -2.25 ± 0.62 |
| Week 4 | -5.54 ± 0.70 | -5.85 ± 0.71 | -5.94 ± 0.70 | -7.00 ± 0.70 | -5.75 ± 0.71 | -6.71 ± 0.70 | -3.87 ± 0.70 |
| Week 6 | -6.26 ± 0.69 | -6.90 ± 0.70 | -7.36 ± 0.69 | -7.68 ± 0.69 | -6.89 ± 0.69 | -8.02 ± 0.69 | -4.94 ± 0.69 |
| Week 8 | -6.50 ± 0.79 | -7.45 ± 0.80 | -7.95 ± 0.79 | -7.83 ± 0.79 | -6.90 ± 0.79 | -8.38 ± 0.78 | -4.51 ± 0.80 |
Twenty-eight tender/painful joint count included the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. Artificial joints were not assessed. These joints were assessed by a joint assessor, who was blinded to the participant's safety data, previous efficacy data and treatment randomization, to determine the number of joints that were considered tender or painful, and swollen.
| Joints | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Swollen-Joint Counts at Week 12 (Descriptive Statistics) | -6.20 ± 6.21 | -5.98 ± 4.81 | -5.86 ± 6.17 | -5.58 ± 6.24 | -7.43 ± 5.82 | -7.07 ± 5.02 | -6.17 ± 5.48 |
The CRP was collected at each applicable clinic visit and analyzed by a central laboratory. In order to assist with the data clean-up at the end of the study, the CRP results were unblinded to the sponsor at the time of the last subject's last visit. All statistics presented below are derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction and baseline value; unstructured covariance matrix was used.
| mg/L | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Week 2 | -7.29 ± 2.89 | -12.95 ± 2.82 | -13.73 ± 2.87 | -18.92 ± 2.78 | -8.25 ± 2.87 | -16.90 ± 2.86 | -2.80 ± 2.89 |
| Week 4 | -9.77 ± 2.77 | -14.33 ± 2.78 | -11.52 ± 2.81 | -16.57 ± 2.75 | -3.92 ± 2.81 | -17.49 ± 2.76 | -6.35 ± 2.77 |
| Week 6 | -9.35 ± 2.51 | -16.16 ± 2.53 | -13.05 ± 2.49 | -13.81 ± 2.51 | -6.54 ± 2.52 | -16.85 ± 2.46 | -3.93 ± 2.53 |
| Week 8 | -7.29 ± 2.49 | -14.28 ± 2.52 | -14.86 ± 2.47 | -11.98 ± 2.49 | -7.23 ± 2.50 | -17.59 ± 2.44 | -4.19 ± 2.49 |
The CRP was collected at each applicable clinic visit and analyzed by a central laboratory. In order to assist with the data clean-up at the end of the study, the CRP results were unblinded to the sponsor at the time of the last subject's last visit.
| mg/L | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline of CRP at Week 12 (Descriptive Statistics) | 0.72 ± 27.40 | -6.24 ± 23.06 | -4.52 ± 20.35 | -0.64 ± 29.08 | -2.90 ± 16.10 | -9.39 ± 36.10 | -4.07 ± 22.10 |
Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The subject's response was recorded using a 100 mm Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
| mm | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Week 2 | -10.24 ± 2.85 | -18.77 ± 2.79 | -24.72 ± 2.83 | -22.50 ± 2.77 | -10.04 ± 2.83 | -23.51 ± 2.84 | -10.61 ± 2.85 |
| Week 4 | -14.93 ± 3.21 | -24.04 ± 3.22 | -27.98 ± 3.24 | -23.14 ± 3.19 | -17.16 ± 3.24 | -28.31 ± 3.24 | -14.56 ± 3.21 |
| Week 6 | -18.77 ± 3.28 | -30.84 ± 3.28 | -35.00 ± 3.27 | -27.93 ± 3.24 | -23.07 ± 3.27 | -32.34 ± 3.27 | -18.55 ± 3.26 |
| Week 8 | -16.51 ± 3.49 | -29.08 ± 3.52 | -36.88 ± 3.50 | -31.32 ± 3.47 | -25.82 ± 3.50 | -34.60 ± 3.51 | -18.36 ± 3.51 |
Participants answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The subject's response was recorded using a 100 mm Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
| mm | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Patient Global Assessment of Arthritis at Week 12 (Descriptive Statistics) | -14.54 ± 27.33 | -22.26 ± 26.11 | -18.10 ± 25.35 | -16.74 ± 31.57 | -19.24 ± 29.32 | -25.29 ± 29.20 | -17.90 ± 23.14 |
The investigator assessed how the participant's overall arthritis appears at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.
| mm | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Week 2 | -16.35 ± 2.53 | -21.74 ± 2.45 | -22.14 ± 2.48 | -25.21 ± 2.43 | -13.24 ± 2.48 | -22.80 ± 2.48 | -9.29 ± 2.50 |
| Week 4 | -22.25 ± 2.68 | -27.03 ± 2.64 | -30.72 ± 2.66 | -28.95 ± 2.62 | -20.94 ± 2.66 | -31.16 ± 2.66 | -15.00 ± 2.64 |
| Week 6 | -25.58 ± 2.68 | -32.54 ± 2.67 | -34.79 ± 2.66 | -32.79 ± 2.63 | -28.54 ± 2.66 | -33.92 ± 2.66 | -19.48 ± 2.65 |
| Week 8 | -26.24 ± 2.81 | -33.92 ± 2.82 | -38.00 ± 2.79 | -33.71 ± 2.77 | -29.25 ± 2.79 | -35.50 ± 2.79 | -21.52 ± 2.79 |
The investigator assessed how the participant's overall arthritis appears at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.
| mm | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Physician Global Assessment of Arthritis at Week 12 (Descriptive Statistics) | -25.00 ± 21.57 | -28.56 ± 26.41 | -23.04 ± 22.00 | -24.30 ± 28.15 | -27.25 ± 23.71 | -27.25 ± 20.42 | -19.34 ± 27.21 |
Participants assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponds to the magnitude of their pain.
| mm | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Week 2 | -13.41 ± 2.88 | -17.40 ± 2.83 | -24.90 ± 2.86 | -22.86 ± 2.80 | -12.68 ± 2.86 | -24.59 ± 2.87 | -10.54 ± 2.88 |
| Week 4 | -15.55 ± 3.08 | -24.38 ± 3.09 | -29.70 ± 3.10 | -26.08 ± 3.05 | -20.26 ± 3.10 | -29.65 ± 3.11 | -14.28 ± 3.08 |
| Week 6 | -19.03 ± 3.33 | -29.16 ± 3.35 | -34.37 ± 3.33 | -30.15 ± 3.30 | -24.16 ± 3.33 | -34.69 ± 3.34 | -18.80 ± 3.32 |
| Week 8 | -18.95 ± 3.45 | -28.53 ± 3.50 | -37.96 ± 3.46 | -30.91 ± 3.43 | -25.86 ± 3.46 | -37.60 ± 3.47 | -18.26 ± 3.47 |
Participants assessed the severity of their arthritis pain using a 100 mm VAS placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponds to the magnitude of their pain.
| mm | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Pain VAS at Week 12 (Descriptive Statistics) | -17.86 ± 26.70 | -19.40 ± 29.04 | -18.23 ± 27.75 | -16.60 ± 30.50 | -21.52 ± 24.69 | -25.17 ± 29.60 | -16.30 ± 22.41 |
Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
| Units on a scale | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Week 2 | -0.25 ± 0.06 | -0.34 ± 0.06 | -0.33 ± 0.06 | -0.41 ± 0.06 | -0.23 ± 0.06 | -0.41 ± 0.06 | -0.05 ± 0.06 |
| Week 4 | -0.26 ± 0.07 | -0.50 ± 0.07 | -0.43 ± 0.07 | -0.51 ± 0.07 | -0.34 ± 0.07 | -0.58 ± 0.07 | -0.14 ± 0.07 |
| Week 6 | -0.35 ± 0.07 | -0.60 ± 0.07 | -0.52 ± 0.07 | -0.56 ± 0.07 | -0.39 ± 0.07 | -0.68 ± 0.07 | -0.21 ± 0.07 |
| Week 8 | -0.26 ± 0.08 | -0.59 ± 0.08 | -0.60 ± 0.08 | -0.55 ± 0.08 | -0.50 ± 0.08 | -0.77 ± 0.08 | -0.19 ± 0.08 |
Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
| Units on a scale | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in HAQ-DI at Week 12 (Descriptive Statistics) | -0.28 ± 0.63 | -0.57 ± 0.65 | -0.37 ± 0.50 | -0.38 ± 0.50 | -0.52 ± 0.63 | -0.56 ± 0.59 | -0.26 ± 0.56 |
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.
| Units on a scale | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Week 2 | -0.81 ± 0.13 | -1.15 ± 0.13 | -1.21 ± 0.13 | -1.51 ± 0.13 | -0.75 ± 0.13 | -1.23 ± 0.13 | -0.40 ± 0.13 |
| Week 4 | -1.19 ± 0.15 | -1.49 ± 0.15 | -1.71 ± 0.15 | -1.73 ± 0.15 | -1.01 ± 0.15 | -1.67 ± 0.15 | -0.76 ± 0.15 |
| Week 6 | -1.38 ± 0.16 | -1.81 ± 0.16 | -2.01 ± 0.16 | -1.99 ± 0.16 | -1.37 ± 0.16 | -1.98 ± 0.16 | -0.94 ± 0.16 |
| Week 8 | -1.44 ± 0.17 | -1.84 ± 0.17 | -2.22 ± 0.17 | -2.13 ± 0.17 | -1.42 ± 0.17 | -2.14 ± 0.17 | -0.93 ± 0.17 |
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.
| Units on a scale | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in DAS 28-3 CRP at Week 12 (Descriptive Statistics) | -1.30 ± 1.21 | -1.37 ± 1.05 | -1.29 ± 1.14 | -1.25 ± 1.36 | -1.45 ± 1.05 | -1.62 ± 1.00 | -1.13 ± 1.08 |
DAS28-4 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission. All statistics presented below are derived from mixed model with fixed effects for treatment, visit, treatment-by-visit interaction and baseline value; unstructured covariance matrix was used.
| Units on a scale | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Week 2 | -0.88 ± 0.14 | -1.29 ± 0.14 | -1.45 ± 0.14 | -1.69 ± 0.14 | -0.82 ± 0.14 | -1.46 ± 0.14 | -0.52 ± 0.14 |
| Week 4 | -1.29 ± 0.16 | -1.68 ± 0.16 | -1.97 ± 0.16 | -1.90 ± 0.16 | -1.15 ± 0.16 | -1.92 ± 0.16 | -0.90 ± 0.16 |
| Week 6 | -1.51 ± 0.18 | -2.06 ± 0.18 | -2.32 ± 0.18 | -2.21 ± 0.18 | -1.56 ± 0.18 | -2.27 ± 0.18 | -1.12 ± 0.18 |
| Week 8 | -1.55 ± 0.19 | -2.07 ± 0.19 | -2.53 ± 0.19 | -2.38 ± 0.19 | -1.65 ± 0.19 | -2.44 ± 0.19 | -1.11 ± 0.19 |
DAS28-4 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.
| Units on a scale | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in DAS28-4(CRP) at Week 12 (Descriptive Statistics) | -1.39 ± 1.31 | -1.56 ± 1.17 | -1.42 ± 1.19 | -1.38 ± 1.47 | -1.59 ± 1.22 | -1.80 ± 1.14 | -1.29 ± 1.21 |
The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.
| Units on a scale | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Week 4 | 3.59 ± 1.28 | 4.53 ± 1.26 | 5.22 ± 1.30 | 5.74 ± 1.25 | 3.67 ± 1.29 | 7.23 ± 1.29 | 4.98 ± 1.28 |
| Week 8 | 2.57 ± 1.39 | 6.07 ± 1.41 | 6.03 ± 1.40 | 6.47 ± 1.39 | 5.30 ± 1.40 | 8.76 ± 1.40 | 4.58 ± 1.39 |
The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.
| Units on a scale | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in SF-36v2 Mental Component Scores at Week 12 (Descriptive Statistics) | 3.35 ± 11.99 | 4.19 ± 9.19 | 0.48 ± 8.97 | 2.72 ± 10.67 | 3.08 ± 12.91 | 6.11 ± 12.90 | 4.69 ± 10.72 |
The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.
| Units on a scale | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Week 4 | 3.84 ± 0.92 | 5.00 ± 0.91 | 8.22 ± 0.93 | 6.83 ± 0.90 | 4.28 ± 0.93 | 7.51 ± 0.93 | 2.10 ± 0.92 |
| Week 8 | 5.24 ± 1.03 | 7.85 ± 1.04 | 9.65 ± 1.03 | 7.15 ± 1.02 | 7.06 ± 1.03 | 9.62 ± 1.03 | 3.45 ± 1.03 |
The 36 item Short Form Health Survey (SF-36) (Versions 2, acute version) is a 36 item generic health status measure. It measures 8 general health concepts: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These concepts can also be summarized as physical component score (PCS) and mental component score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). This questionnaire was completed by the participant prior to any procedures being performed at the visit, if possible. The form was then checked by site staff for completeness.
| Units on a scale | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Change From Baseline in SF-36v2 Physical Component Scores at Week 12 (Descriptive Statistics) | 4.64 ± 8.21 | 5.39 ± 7.05 | 7.42 ± 8.56 | 3.91 ± 7.16 | 7.63 ± 7.95 | 5.85 ± 7.32 | 3.23 ± 4.80 |
Collected over 13 weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-04171327 1 mg | — | 0/45 (0%) | 20/45 (44.4%) |
| PF-04171327 5 mg | — | 1/47 (2.1%) | 18/47 (38.3%) |
| PF-04171327 10 mg | — | 2/45 (4.4%) | 22/45 (48.9%) |
| PF-04171327 15 mg | — | 2/48 (4.2%) | 16/48 (33.3%) |
| Prednisone 5 mg | — | 0/45 (0%) | 16/45 (35.6%) |
| Prednisone 10 mg | — | 2/46 (4.3%) | 19/46 (41.3%) |
| Placebo | — | 2/47 (4.3%) | 16/47 (34%) |
| Event | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| Coronary artery diseaseCardiac disorders | 0/45 | 0/47 | 1/45 | 0/48 | 0/45 | 0/46 | 0/47 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/45 | 0/47 | 1/45 | 0/48 | 0/45 | 0/46 | 0/47 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/45 | 0/47 | 0/45 | 0/48 | 0/45 | 1/46 | 0/47 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/45 | 0/47 | 0/45 | 0/48 | 0/45 | 1/46 | 0/47 |
| BronchitisInfections and infestations | 0/45 | 0/47 | 0/45 | 0/48 | 0/45 | 0/46 | 1/47 |
| Cholecystitis infectiveInfections and infestations | 0/45 | 0/47 | 0/45 | 0/48 | 0/45 | 0/46 | 1/47 |
| GlioblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/45 | 1/47 | 0/45 | 0/48 | 0/45 | 0/46 | 0/47 |
| Chest painGeneral disorders | 0/45 | 0/47 | 0/45 | 1/48 | 0/45 | 0/46 | 0/47 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/45 | 0/47 | 0/45 | 1/48 | 0/45 | 0/46 | 0/47 |
| Event | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo |
|---|---|---|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/45 | 1/47 | 1/45 | 0/48 | 1/45 | 5/46 | 0/47 |
| Alanine aminotransferase increasedInvestigations | 2/45 | 1/47 | 4/45 | 0/48 | 0/45 | 3/46 | 3/47 |
| HeadacheNervous system disorders | 1/45 | 0/47 | 0/45 | 1/48 | 0/45 | 4/46 | 0/47 |
| NasopharyngitisInfections and infestations | 1/45 | 3/47 | 3/45 | 2/48 | 0/45 | 1/46 | 1/47 |
| Upper respiratory tract infectionInfections and infestations | 1/45 | 0/47 | 3/45 | 2/48 | 0/45 | 0/46 | 1/47 |
| ArthritisMusculoskeletal and connective tissue disorders | 1/45 | 0/47 | 3/45 | 1/48 | 0/45 | 0/46 | 1/47 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 1/45 | 0/47 | 0/45 | 2/48 | 3/45 | 0/46 | 1/47 |
| HypertensionVascular disorders | 0/45 | 3/47 | 0/45 | 1/48 | 1/45 | 0/46 | 0/47 |
| Abdominal painGastrointestinal disorders | 0/45 | 0/47 | 2/45 | 0/48 | 1/45 | 0/46 | 0/47 |
| DiarrhoeaGastrointestinal disorders | 1/45 | 0/47 | 0/45 | 2/48 | 2/45 | 2/46 | 0/47 |
| Age, Continuous(Years) | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 50.4 ± 14.2 | 55.1 ± 12.1 | 54.7 ± 13.1 | 54.0 ± 11.1 | 52.9 ± 11.2 | 57.3 ± 10.7 | 55.2 ± 13.2 | 54.3 ± 12.3 |
| Sex: Female, Male(Participants) | PF-04171327 1 mg | PF-04171327 5 mg | PF-04171327 10 mg | PF-04171327 15 mg | Prednisone 5 mg | Prednisone 10 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 33 | 38 | 34 | 37 | 39 | 41 | 37 | 259 |
| Male | 12 | 9 | 11 | 11 | 6 | 5 | 10 | 64 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Sep 2011 to primary completion in Jun 2014, 32 months.
Results were first posted in Sep 2024, 10 years 3 months after primary completion. A results delay was requested in Dec 2018.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 32 months is above that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fosdagrocorat · Prednisone